Travere Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2012
Net Income	-161.13	-111.4	-278.48	-180.09	-169.43	-146.43	Upgrade
Depreciation & Amortization	38.87	38.53	20.72	12.75	24.58	20.41	Upgrade
Share-Based Compensation	40.24	44.25	38.14	29.57	23.61	21.11	Upgrade
Other Operating Activities	-235.89	-251.4	33.33	122.99	78.5	46.7	Upgrade
Operating Cash Flow	-317.91	-280.02	-186.29	-14.79	-42.74	-58.21	Upgrade
Capital Expenditures	-20.76	-42.26	-28.56	-24.15	-24.57	-15.57	Upgrade
Acquisitions	0	0	0	0	-95.28	0	Upgrade
Change in Investments	11.07	-109.37	-3.4	-113.47	58.52	35.43	Upgrade
Other Investing Activities	207.4	207.4	-0.6	-	-	-	Upgrade
Investing Cash Flow	197.71	55.78	-32.55	-137.62	-61.33	19.86	Upgrade
Share Issuance / Repurchase	4.11	222.23	27.11	239.89	137.46	3.4	Upgrade
Debt Issued / Paid	0	0	95.04	0	0	0	Upgrade
Other Financing Activities	-2.88	-3.48	-4.58	-8.2	-9.75	-5.47	Upgrade
Financing Cash Flow	1.23	218.75	117.57	231.68	127.71	-2.08	Upgrade
Exchange Rate Effect	0.84	1.98	-2.79	1.71	-1.31	-0.01	Upgrade
Net Cash Flow	-118.13	-3.51	-104.07	80.98	22.34	-40.44	Upgrade
Free Cash Flow	-338.67	-322.28	-214.85	-38.94	-67.31	-73.78	Upgrade
Free Cash Flow Margin	-184.84%	-221.90%	-196.28%	-29.54%	-33.94%	-42.08%	Upgrade
Free Cash Flow Per Share	-4.39	-4.34	-3.37	-0.65	-1.42	-1.74	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).